Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 26 Rituximab 17 Etoposide 16 Methotrexate 15 Dexamethasone 15 Cytarabine 15 Vincristine 14 Prednisone 11 Doxorubicin 11 Radiotherapy 10 blinatumomab 8 fludarabine 7 Mercaptopurine 7 Filgrastim 7 Daunorubicin 7 Asparaginase 7 pegaspargase 6 Granulocyte Colony-Stimulating Factor 6 Methylprednisolone 5 Drug Therapy 5 Dasatinib 5 venetoclax 4 prednylidene 4 etoposide phosphate 4 deltacortene 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 4 Busulfan 4 Bendamustine Hydrochloride 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × zanolimumab × Lymphoid × Clear all

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡